DBV Technologies Stock Rebounds on its €2.75 Support Following the VITESSE Study
The French biotech regains momentum in a well-oriented Parisian market. The stock attempts to stabilize its price after several weeks of significant decline, as new clinical data on its peanut allergy patch were unveiled at the beginning of the week.
A Technical Rebound with an RSI at 29, at the Lower End of Recent Ranges
DBV Technologies stock has risen by 1.52% to €2.80, in a SBF 120 that is up by 0.79%. The stock has recovered from the support threshold of €2.75, tested at the start of the session, while an RSI at 29 indicates seller exhaustion over the last few weeks. However, the biotech remains below its three moving averages, with the MM50 at €3.37, making the price 16.97% lower than this average.
Over a month, the decline reaches nearly 18%, and exceeds 30% over three months, which places today's rebound in a still largely bearish dynamic. Over twelve months, however, the performance remains positive, at more than 73%.
Positive Data from the VITESSE Study and Presentation of the THRIVE Protocol at EAACI
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
On Monday, the company released new positive data from the phase 3 VITESSE study on its epicutaneous immunotherapy patch for children allergic to peanuts. The phase 2 THRIVE study protocol, which expands the evaluation to infants aged 6 to 12 months, will also be presented at the 2026 Congress of the European Academy of Allergy and Clinical Immunology, from June 12 to 15 in Istanbul. This scientific event occurs as CEO Daniel Tassé spoke on Tuesday at the Global Healthcare Conference by Goldman Sachs in Miami.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1M€dedollars
Net income: -47,6M€dedollars
Free cash flow: -49M€dedollars
Guidance from the release
Toute l'équipe de DBV démontre une focalisation et une rigueur exceptionnelles alors que nous abordons des étapes décisives au cours des prochains mois.
Risks mentioned
Augmentation significative des dépenses de R&D.
Perte nette en hausse à 47,6 millions de dollars.
Opportunities identified
Dépôt de la demande de licence biologique prévu pour 2026.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
